Avalo Therapeutics, Inc. · NASDAQ:AVTX

Sullivan Christopher Ryan received 39,900 Avalo Therapeutics, Inc. shares as an award (Form 4)

Traded May 21, 2026 · Filed May 26, 2026

On May 21, 2026, Sullivan Christopher Ryan (Chief Financial Officer) received 39,900 Avalo Therapeutics, Inc. shares as an award, leaving 40,323 shares. Filed May 26, 2026 (Form 4).

Awarded
39,900 shares
Holding after
40,323 shares
Trading plan
No
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 21, 2026Common StockAward39,90040,323Direct

Source

View original at SEC

Related